Sanofi and Teva to Collaborate on Inflammatory Bowel Disease Treatment

By Lalit Mishra

Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)

Published: 13 Oct-2023

DOI: 10.3833/pdr.v2023.i10.2809     ISSN: 1756-7874

Section: Research & Development



In a significant move towards bolstering its autoimmune and gastroenterology disease portfolio, Sanofi has entered into a strategic collaboration with Teva Pharmaceuticals to co-develop and co-commercialise Teva’s novel anti-TL1A therapy, TEV’574, for the treatment of ulcerative colitis and Crohn's disease, in a deal that could be worth up to US$1...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details